Levetiracetam Injection
Product Images NDC 66298-0447

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 66298-0447). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hp Halden Pharma As, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Box0 (Box0)

Levetiracetam 10 mg/mL injection in 0.75% sodium chloride, 100 mL single-dose dual port bag for intravenous infusion. The label includes concentration details (1,000 mg in 100 mL), usage instructions, cautions, storage conditions (20° to 25°C), and manufacturer information: Fresenius Kabi, Lake Zurich, IL, made in Norway. Barcode and lot/expiration placeholders are shown.*

FDA Label Image

Box2 (Box2)

Label for Levetiracetam 10 mg/mL Injection in 0.75% Sodium Chloride, supplied as 1,000 mg in 100 mL single-dose bags. The package contains 24 bags for intravenous infusion, manufactured for Fresenius Kabi, Lake Zurich, IL, made in Norway. The label includes storage instructions and caution regarding sterility.*

FDA Label Image

Box3 (Box3)

Levetiracetam injection label showing 1000 mg in 100 mL (10 mg per mL) in 0.75% sodium chloride solution. The label specifies administration as intravenous infusion only and includes a QR code. It is marked as prescription use only.*

FDA Label Image

Label (Label)

A data table comparing the percentage of various adverse reactions reported in patients receiving Levetiracetam injection (N=769) versus placebo (N=439). The table lists adverse reactions such as asthenia, somnolence, headache, infection, dizziness, pain, pharyngitis, depression, and others with corresponding percentage values for each group.*

FDA Label Image

Label03 (Label03)

A bar chart comparing the percentage of patients across three groups: Placebo (111 patients), Levetiracetam 1,000 mg/day (106 patients), and Levetiracetam 2,000 mg/day (105 patients). The chart shows a higher percentage of patients in the Levetiracetam groups compared to placebo, with 6.3% for placebo, 20.8% for 1,000 mg/day, and 35.2% for 2,000 mg/day. Statistically significant differences versus placebo are indicated with an asterisk.*

FDA Label Image

Label04 (Label04)

A bar chart comparing the percentage of patients between two groups: Placebo (N=104) with 14.4%, and Levetiracetam 3,000 mg/day (N=180) with 39.4%. The y-axis shows the percentage of patients from 0% to 45%. An asterisk indicates statistical significance of Levetiracetam versus placebo.*

FDA Label Image

Label05 (Label05)

A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The placebo group (N=84) shows 45.2%, while the Levetiracetam group (N=79) shows 72.2%. The chart notes a statistically significant difference between Levetiracetam and placebo.*

FDA Label Image

Label06 (Label06)

FDA Label Image

Label2 (Label2)

A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1,000 mg/day, and Levetiracetam 3,000 mg/day. Percentages are 7.4% for Placebo (N=95), 37.1% for Levetiracetam 1,000 mg/day (N=97), and 39.6% for Levetiracetam 3,000 mg/day (N=101). Statistically significant differences versus placebo are indicated for both Levetiracetam groups.*

FDA Label Image

Chemical Structure (Levetiracetam 01)

Chemical structure of the active ingredient levetiracetam, showing its molecular arrangement with a pyrrolidone ring attached to an ethyl group and an amide functional group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.